Table 2. Use of medications and occurrences of adverse events by study participants (n=67). Ribeirão Preto, SP, Brasil, 2016.
Parameter | N (%)* |
---|---|
Previously used drugs metabolized by CYP2C9 | 66 (98.5%) |
Ibuprofen | 32 (17.2%) |
Acetylsalicylic Acid | 54 (29%) |
Diclofenac | 55 (29.6%) |
Celecoxib | 12 (6.5%) |
Rosuvastatin | 12 (6.5%) |
Prasugrel | 1 (0.5%) |
Phenytoin | 1 (0.5%) |
Irbesartan | 0 (0%) |
Losartan | 17 (9.1%) |
Warfarin | 2 (1.1%) |
Number of medications already used | |
= 1 | 10 (15.2%) |
2 - 4 | 50 (75.8%) |
>4 | 6 (9%) |
Occurrence of adverse events | 19 (27.5%) |
Nausea | 1 (5.3%) |
Headache | 1 (5.3%) |
Vertigo | 1 (5.3%) |
Decreased urinary output | 1 (5.3%) |
Pain in the legs | 1 (5.3%) |
Paresthesia | 2 (10.4%) |
Stomach pain | 8 (42.1%) |
Allergic reactions | 4 (21%) |
Medications related to the occurrence of adverse events | |
Aspirin | 9 (42.8%) |
Diclofenac | 8 (38.1%) |
Losartan | 2 (9.5%) |
Rosuvastatin | 1 (4.8%) |
Celecoxib | 1 (4.8%) |
n (%) = Values in number of observations or percentage frequency